Frequent MYC coamplification and DNA hypomethylation of multiple genes on 8q in 8p11-p12-amplified breast carcinomas

Oncogenesis

Volumn 3, Issue 3, 2014, Pages

  Parris, T Z ^a   Kovacs A ^b   Hajizadeh, S ^b   Nemes, S ^c,d   Semaan, M ^a   Levin, M ^a   Karlsson, P ^a   Helou, K ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^d Regional Cancer Center West   (Sweden)

Author keywords

8p11 p12; breast cancer; DNA amplification; DNA methylation; MYC

Indexed keywords

AUTOTAXIN; FABP5 PROTEIN; IMPAD1 PROTEIN; MYC PROTEIN; NDRG1 PROTEIN; PLEKHF2 PROTEIN; PROTEIN; RRM2B PROTEIN; SQLE PROTEIN; TAF2 PROTEIN; TATDN1 PROTEIN; TRPS1 PROTEIN; UNCLASSIFIED DRUG; VPS13B PROTEIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER GROWTH; CELL DIFFERENTIATION; CHROMOSOME 8P; CHROMOSOME 8P11; CHROMOSOME 8P12; CHROMOSOME 8Q; CLONE; CONTROLLED STUDY; COPY NUMBER VARIATION; CPG ISLAND; DISEASE FREE SURVIVAL; DNA DETERMINATION; DNA METHYLATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE REARRANGEMENT; GENOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RNA TRANSCRIPTION; VERY ELDERLY;

EID: 84918525550     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2014.8     Document Type: Article

References (57)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Baylin SB. The cancer epigenome: its origins, contributions to tumorigenesis, and translational implications. Proc Am Thorac Soc 2012; 9: 64-65.
3. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 2005; 45: 629-656.
4. Gal-Yam EN, Saito Y, Egger G, Jones PA. Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med 2008; 59: 267-280.
5. Huang Y, Nayak S, Jankowitz R, Davidson NE, Oesterreich S. Epigenetics in breast cancer: what's new? Breast Cancer Res 2011; 13: 225.
6. Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev 2004; 18: 2315-2335.
7. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16: 6-21.
8. Costello JF, Plass C. Methylation matters. J Med Genet 2001; 38: 285-303.
9. Fuks F. DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev 2005; 15: 490-495.
10. Heard E, Disteche CM. Dosage compensation in mammals: fine-tuning the expression of the X chromosome. Genes Dev 2006; 20: 1848-1867.
11. Adelaide J, Chaffanet M, Imbert A, Allione F, Geneix J, Popovici C et al. Chromosome region 8p11-p21: refined mapping and molecular alterations in breast cancer. Genes Chromosomes Cancer 1998; 22: 186-199.
12. Theillet C, Adelaide J, Louason G, Bonnet-Dorion F, Jacquemier J, Adnane J et al. FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chromosomes Cancer 1993; 7: 219-226.
13. Thor AD, Eng C, Devries S, Paterakos M, Watkin WG, Edgerton S et al. Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. Hum Pathol 2002; 33: 628-631.
14. Roque L, Rodrigues R, Martins C, Ribeiro C, Ribeiro MJ, Martins AG et al. Comparative genomic hybridization analysis of a pleuropulmonary blastoma. Cancer Genet Cytogenet 2004; 149: 58-62.
15. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009; 41: 1238-1242.
16. Boelens MC, Kok K, van der Vlies P, van der Vries G, Sietsma H, Timens W et al. Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis. Lung cancer 2009; 66: 372-378.
17. Mahmood SF, Gruel N, Nicolle R, Chapeaublanc E, Delattre O, Radvanyi F et al. PPAPDC1B and WHSC1L1 are common drivers of the 8p11-12 amplicon, not only in breast tumors but also in pancreatic adenocarcinomas and lung tumors. Am J Pathol 2013; 183: 1634-1644.
18. Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y et al. High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci USA 2005; 102: 9625-9630.
19. Simon R, Richter J, Wagner U, Fijan A, Bruderer J, Schmid U et al. Highthroughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res 2001; 61: 4514-4519.
20. Williams SV, Platt FM, Hurst CD, Aveyard JS, Taylor CF, Pole JC et al. High-resolution analysis of genomic alteration on chromosome arm 8p in urothelial carcinoma. Genes Chromosomes Cancer 2010; 49: 642-659.
21. Knuutila S, Bjorkqvist AM, Autio K, Tarkkanen M, Wolf M, Monni O et al. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol 1998; 152: 1107-1123.
22. Paterson AL, Pole JC, Blood KA, Garcia MJ, Cooke SL, Teschendorff AE et al. Co-amplification of 8p12 and 11q13 in breast cancers is not the result of a single genomic event. Genes Chromosomes Cancer 2007; 46: 427-439.
23. Mö llerstrom E, Delle U, Danielsson A, Parris T, Olsson B, Karlsson P et al. Highresolution genomic profiling to predict 10-year overall survival in node-negative breast cancer. Cancer Genet Cytogenet 2010; 198: 79-89.
24. Parris TZ, Danielsson A, Nemes S, Kovacs A, Delle U, Fallenius G et al. Clinical implications of gene dosage and gene expression patterns in diploid breast carcinoma. Clin Cancer Res 2010; 16: 3860-3874.
25. Kwek SS, Roy R, Zhou H, Climent J, Martinez-Climent JA, Fridlyand J et al. Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis. Oncogene 2009; 28: 1892-1903.
26. Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, Rouge C et al. Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol Cancer Res 2005; 3: 655-667.
27. Holland DG, Burleigh A, Git A, Goldgraben MA, Perez-Mancera PA, Chin SF et al. ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med 2011; 3: 167-180.
28. Sircoulomb F, Nicolas N, Ferrari A, Finetti P, Bekhouche I, Rousselet E et al. ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med 2011; 3: 153-166.
29. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010; 70: 2085-2094.
30. Zhang X, Mu X, Huang O, Xie Z, Jiang M, Geng M et al. Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling. PLoS One 2013; 8: e72053.
31. Bernard-Pierrot I, Gruel N, Stransky N, Vincent-Salomon A, Reyal F, Raynal V et al. Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. Cancer Res 2008; 68: 7165-7175.
32. Yang ZQ, Liu G, Bollig-Fischer A, Giroux CN, Ethier SP. Transforming properties of 8p11-12 amplified genes in human breast cancer. Cancer Res 2010; 70: 8487-8497.
33. Yang ZQ, Streicher KL, Ray ME, Abrams J, Ethier SP. Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. Cancer Res 2006; 66: 11632-11643.
34. An CH, Kim YR, Kim HS, Kim SS, Yoo NJ, Lee SH. Frameshift mutations of vacuolar protein sorting genes in gastric and colorectal cancers with microsatellite instability. Hum Pathol 2012; 43: 40-47.
35. Edgren H, Murumagi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K et al. Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biol 2011; 12: R6.
36. Schulte I, Batty EM, Pole JC, Blood KA, Mo S, Cooke SL et al. Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes. BMC Genomics 2012; 13: 719.
37. Chin SF, Teschendorff AE, Marioni JC, Wang Y, Barbosa-Morais NL, Thorne NP et al. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol 2007; 8: R215.
38. Helms MW, Kemming D, Pospisil H, Vogt U, Buerger H, Korsching E et al. Squalene epoxidase, located on chromosome 8q24.1, is upregulated in 8q\+ breast cancer and indicates poor clinical outcome in stage I and II disease. Br J Cancer 2008; 99: 774-780.
39. Sircoulomb F, Bekhouche I, Finetti P, Adelaide J, Ben Hamida A, Bonansea J et al. Genome profiling of ERBB2-amplified breast cancers. BMC Cancer 2010; 10: 539.
40. Chang GT, Jhamai M, van Weerden WM, Jenster G, Brinkmann AO. The TRPS1 transcription factor: androgenic regulation in prostate cancer and high expression in breast cancer. Endocr Relat Cancer 2004; 11: 815-822.
41. Chen JQ, Bao Y, Litton J, Xiao L, Zhang HZ, Warneke CL et al. Expression and relevance of TRPS-1: a new GATA transcription factor in breast cancer. Horm Cancer 2011; 2: 132-143.
42. Fotovati A, Abu-Ali S, Kage M, Shirouzu K, Yamana H, Kuwano M. N-myc downstream-regulated gene 1 (NDRG1) a differentiation marker of human breast cancer. Pathol Oncol Res 2011; 17: 525-533.
43. Mao XY, Fan CF, Wei J, Liu C, Zheng HC, Yao F et al. Increased N-myc downstreamregulated gene 1 expression is associated with breast atypia-to-carcinoma progression. Tumour Biol 2011; 32: 1271-1276.
44. Nagai MA, Gerhard R, Fregnani JH, Nonogaki S, Rierger RB, Netto MM et al. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Res Treat 2011; 126: 1-14.
45. Han LL, Hou L, Zhou MJ, Ma ZL, Lin DL, Wu L et al. Aberrant NDRG1 methylation associated with its decreased expression and clinicopathological significance in breast cancer. J Biomed Sci 2013; 20: 52.
46. Gokmen-Polar Y, Liu Y, Toroni RA, Sanders KL, Mehta R, Badve S et al. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models. Breast Cancer Res Treat 2012; 136: 673-682.
47. Sommer EM, Dry H, Cross D, Guichard S, Davies BR, Alessi DR. Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors. Biochem J 2013; 452: 499-508.
48. Carson C, Omolo B, Chu H, Zhou Y, Sambade MJ, Peters EC et al. A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines. Pigment Cell Melanoma Res 2012; 25: 514-526.
49. Kuo ML, Sy AJ, Xue L, Chi M, Lee MT, Yen T et al. RRM2B suppresses activation of the oxidative stress pathway and is up-regulated by p53 during senescence. Sci Rep 2012; 2: 822.
50. Thurn KT, Thomas S, Raha P, Qureshi I, Munster PN. Histone deacetylase regulation of ATM-mediated DNA damage signaling. Mol Cancer Ther 2013; 12: 2078-2087.
51. Malkowska M, Kokoszynska K, Rychlewski L, Wyrwicz L. Structural bioinformatics of the general transcription factor TFIID. Biochimie 2013; 95: 680-691.
52. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7: 96.
53. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C et al. Definition of clinically distinct molecular subtypes in estrogen receptorpositive breast carcinomas through genomic grade. J Clin Oncol 2007; 25: 1239-1246.
54. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98: 262-272.
55. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
56. Helou K, Wallenius V, Qiu Y, Ohman F, Stahl F, Klinga-Levan K et al. Amplification and overexpression of the hepatocyte growth factor receptor (HGFR/MET) in rat DMBA sarcomas. Oncogene 1999; 18: 3226-3234.
57. Wang D, Yan L, Hu Q, Sucheston LE, Higgins MJ, Ambrosone CB et al. IMA: an R package for high-throughput analysis of Illumina's 450K Infinium methylation data. Bioinformatics 2012; 28: 729-730.